Cargando…

Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA

We have reported that the plasma zinc concentration gradually decreases with the progression of fibrosis and is related to hepatocellular carcinoma (HCC) development. The aim of this study was to examine the impact of the zinc concentration on HCC development (study 1) and the relationship between z...

Descripción completa

Detalles Bibliográficos
Autores principales: Hosui, Atsushi, Tanimoto, Takashi, Okahara, Toru, Ashida, Munehiro, Ohnishi, Kohsaku, Wakahara, Yuhei, Kusumoto, Yukihiro, Yamaguchi, Toshio, Sueyoshi, Yuka, Hirao, Motohiro, Yamada, Takuya, Hiramatsu, Naoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631098/
https://www.ncbi.nlm.nih.gov/pubmed/34752016
http://dx.doi.org/10.1002/hep4.1782
_version_ 1784607484445458432
author Hosui, Atsushi
Tanimoto, Takashi
Okahara, Toru
Ashida, Munehiro
Ohnishi, Kohsaku
Wakahara, Yuhei
Kusumoto, Yukihiro
Yamaguchi, Toshio
Sueyoshi, Yuka
Hirao, Motohiro
Yamada, Takuya
Hiramatsu, Naoki
author_facet Hosui, Atsushi
Tanimoto, Takashi
Okahara, Toru
Ashida, Munehiro
Ohnishi, Kohsaku
Wakahara, Yuhei
Kusumoto, Yukihiro
Yamaguchi, Toshio
Sueyoshi, Yuka
Hirao, Motohiro
Yamada, Takuya
Hiramatsu, Naoki
author_sort Hosui, Atsushi
collection PubMed
description We have reported that the plasma zinc concentration gradually decreases with the progression of fibrosis and is related to hepatocellular carcinoma (HCC) development. The aim of this study was to examine the impact of the zinc concentration on HCC development (study 1) and the relationship between zinc intake and HCC development (study 2) in patients with hepatitis C virus (HCV) eradicated by direct‐acting antivirals (DAAs). A total of 599 sustained virological response (SVR) patients treated with DAAs without a history of HCC were retrospectively analyzed in this study. Eighty patients received supplemental zinc (Zn treatment group), and 519 patients did not receive zinc (no Zn treatment group). In study 1, the cumulative incidence rate of HCC was compared between the Zn treatment group and the no Zn treatment group. In study 2, the risk factors for HCC development were examined in the no Zn treatment group. In study 1, in the Zn treatment group, HCC did not develop during follow‐up, and the cumulative risk of HCC was significantly lower in the Zn treatment group than in the no Zn treatment group (P = 0.048). In study 2, the 1‐year and 3‐year cumulative incidence rates of HCC were 1.8% and 5.6%, respectively. The risk factors for HCC identified by multivariate analysis were male sex, cirrhosis, low platelet count before treatment, and low serum zinc concentration 12 weeks after the end of DAA therapy. Conclusion: The Zn concentration is related to HCC development in patients with HCV eradicated by DAA therapy. Oral zinc supplementation is recommended as a means of suppressing HCC development in patients who have achieved SVR.
format Online
Article
Text
id pubmed-8631098
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-86310982021-12-06 Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA Hosui, Atsushi Tanimoto, Takashi Okahara, Toru Ashida, Munehiro Ohnishi, Kohsaku Wakahara, Yuhei Kusumoto, Yukihiro Yamaguchi, Toshio Sueyoshi, Yuka Hirao, Motohiro Yamada, Takuya Hiramatsu, Naoki Hepatol Commun Original Articles We have reported that the plasma zinc concentration gradually decreases with the progression of fibrosis and is related to hepatocellular carcinoma (HCC) development. The aim of this study was to examine the impact of the zinc concentration on HCC development (study 1) and the relationship between zinc intake and HCC development (study 2) in patients with hepatitis C virus (HCV) eradicated by direct‐acting antivirals (DAAs). A total of 599 sustained virological response (SVR) patients treated with DAAs without a history of HCC were retrospectively analyzed in this study. Eighty patients received supplemental zinc (Zn treatment group), and 519 patients did not receive zinc (no Zn treatment group). In study 1, the cumulative incidence rate of HCC was compared between the Zn treatment group and the no Zn treatment group. In study 2, the risk factors for HCC development were examined in the no Zn treatment group. In study 1, in the Zn treatment group, HCC did not develop during follow‐up, and the cumulative risk of HCC was significantly lower in the Zn treatment group than in the no Zn treatment group (P = 0.048). In study 2, the 1‐year and 3‐year cumulative incidence rates of HCC were 1.8% and 5.6%, respectively. The risk factors for HCC identified by multivariate analysis were male sex, cirrhosis, low platelet count before treatment, and low serum zinc concentration 12 weeks after the end of DAA therapy. Conclusion: The Zn concentration is related to HCC development in patients with HCV eradicated by DAA therapy. Oral zinc supplementation is recommended as a means of suppressing HCC development in patients who have achieved SVR. John Wiley and Sons Inc. 2021-08-03 /pmc/articles/PMC8631098/ /pubmed/34752016 http://dx.doi.org/10.1002/hep4.1782 Text en © 2021 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Hosui, Atsushi
Tanimoto, Takashi
Okahara, Toru
Ashida, Munehiro
Ohnishi, Kohsaku
Wakahara, Yuhei
Kusumoto, Yukihiro
Yamaguchi, Toshio
Sueyoshi, Yuka
Hirao, Motohiro
Yamada, Takuya
Hiramatsu, Naoki
Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
title Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
title_full Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
title_fullStr Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
title_full_unstemmed Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
title_short Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
title_sort oral zinc supplementation decreases the risk of hcc development in patients with hcv eradicated by daa
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631098/
https://www.ncbi.nlm.nih.gov/pubmed/34752016
http://dx.doi.org/10.1002/hep4.1782
work_keys_str_mv AT hosuiatsushi oralzincsupplementationdecreasestheriskofhccdevelopmentinpatientswithhcveradicatedbydaa
AT tanimototakashi oralzincsupplementationdecreasestheriskofhccdevelopmentinpatientswithhcveradicatedbydaa
AT okaharatoru oralzincsupplementationdecreasestheriskofhccdevelopmentinpatientswithhcveradicatedbydaa
AT ashidamunehiro oralzincsupplementationdecreasestheriskofhccdevelopmentinpatientswithhcveradicatedbydaa
AT ohnishikohsaku oralzincsupplementationdecreasestheriskofhccdevelopmentinpatientswithhcveradicatedbydaa
AT wakaharayuhei oralzincsupplementationdecreasestheriskofhccdevelopmentinpatientswithhcveradicatedbydaa
AT kusumotoyukihiro oralzincsupplementationdecreasestheriskofhccdevelopmentinpatientswithhcveradicatedbydaa
AT yamaguchitoshio oralzincsupplementationdecreasestheriskofhccdevelopmentinpatientswithhcveradicatedbydaa
AT sueyoshiyuka oralzincsupplementationdecreasestheriskofhccdevelopmentinpatientswithhcveradicatedbydaa
AT hiraomotohiro oralzincsupplementationdecreasestheriskofhccdevelopmentinpatientswithhcveradicatedbydaa
AT yamadatakuya oralzincsupplementationdecreasestheriskofhccdevelopmentinpatientswithhcveradicatedbydaa
AT hiramatsunaoki oralzincsupplementationdecreasestheriskofhccdevelopmentinpatientswithhcveradicatedbydaa